Pazopanib showed favorable inhibitory effects on tumor growth, lymph node metastasis, and tumor lymphangiogenesis in an orthotopic colorectal cancer model.311 Sunitinib is a small-molecule inhibitor that targets VEGFRs, PDGFRs, and c-Kit.312 Sunitinib treatment markedly reduced pathological corneal lymphangiogenesis and angiogenesis.313 However, Dufies et al. reported that sunitinib treatment also induced lymphangiogenesis in the renal cell carcinoma context by activating VEGFC transcription and stabilizing VEGFC mRNA.314. This evidence concerns the gene VEGFC and renal cell carcinoma.